Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2022
|
| gptkbp:ATCCode |
C01EB25
|
| gptkbp:blackBoxWarning |
risk of heart failure due to systolic dysfunction
|
| gptkbp:contraindication |
concurrent use with certain CYP2C19 or CYP3A4 inhibitors
|
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:form |
capsule
|
| gptkbp:genericName |
gptkb:mavacamten
|
| gptkbp:halfLife |
6-9 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Camzyos
|
| gptkbp:indication |
obstructive hypertrophic cardiomyopathy
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Bristol_Myers_Squibb
|
| gptkbp:mechanismOfAction |
cardiac myosin inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:atrial_fibrillation
heart failure dizziness syncope |
| gptkbp:status |
FDA approved
|
| gptkbp:bfsParent |
gptkb:mavacamten
|
| gptkbp:bfsLayer |
8
|